Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.49 |
| ▸ | RAB9A | P51151 | 11/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5692763 | 0.82 | NPC1 (0.45) | NPC1RAB9AKMT2AMEN1SYK | |
| SCHEMBL23604249 | 0.82 | NPC1 (0.55) | NPC1RAB9AKMT2AMEN1TP53 | |
| SCHEMBL1857119 | 0.82 | NPC1 (0.45) | NPC1RAB9AKMT2AMEN1TP53 | |
| SCHEMBL11888091 | 0.79 | KMT2A (0.46) | NPC1RAB9AKMT2AMEN1SYK | |
| SCHEMBL11949099 | 0.77 | ALDH1A1 (0.46) | NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1856772 | 0.77 | CREBBP (0.47) | NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6066037 | 0.75 | CREBBP (0.45) | NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL4048871 | 0.74 | ELANE (0.52) | NPC1RAB9AKMT2AMEN1SYK | |
| SCHEMBL1858331 | 0.73 | KMT2A (0.41) | NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL287396 | 0.73 | TRPV1 (0.48) | NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| CN-1512987-A | Novel 1H-indazole compound | ������������ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1380576-A1 | NOVEL 1H-INDAZOLE COMPOUND | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | NPC1 1164/4885RAB9A 2355/4885KMT2A 2212/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | NPC1 1171/4885RAB9A 2697/4885KMT2A 2834/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | NPC1 1164/4885RAB9A 2355/4885KMT2A 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.